Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Uterine Cervical Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Neoplasms 2Melanoma 2Lymphoma, Follicular 2Lung Neoplasms 2Endometrial Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Sarcoma 1Rhabdoid Tumor 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Lethal Congenital Contracture Syndrome 2 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Carboplatin 24Pemetrexed 18Cisplatin 17Paclitaxel 14pembrolizumab 13Gemcitabine 8osimertinib 7durvalumab 6Docetaxel 6Nivolumab 5Erlotinib Hydrochloride 5130-nm albumin-bound paclitaxel 5capmatinib 3brigatinib 3anlotinib 3Gefitinib 3Drug Therapy 3vosaroxin 2volociximab 2sintilimab 2pralsetinib 2ensartinib 2atezolizumab 2aflibercept 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Oncolytic Virotherapy 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Itraconazole × Thoracic × Clear all
NCT05150691 2026-01-28

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

DualityBio Inc.

Phase 1/2 Recruiting
796 enrolled
BreastGastrointestinalGynecologicThoracic

Bile Duct Neoplasms, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡